Michael Cooper, DO
Psychiatry · Festus, MONPI 1386059277
Payments from drug & device makers
Across 497 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$727
- Otsuka America Pharmaceutical, Inc.$690
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$657
- Neurocrine Biosciences, Inc.$644
- plus $3K from 21 others
What the payments were for
- Food & beverage$7,95199%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 101 | $1,426 |
| Takeda Pharmaceuticals U.S.A., Inc. | 63 | $1,059 |
| Johnson & Johnson | 53 | $727 |
| Otsuka America Pharmaceutical, Inc. | 39 | $690 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $657 |
| Neurocrine Biosciences, Inc. | 30 | $644 |
| Lundbeck LLC | 39 | $597 |
| Vanda Pharmaceuticals Inc. | 26 | $398 |
| Supernus Pharmaceuticals, Inc. | 24 | $315 |
| Avanir Pharmaceuticals, Inc. | 15 | $277 |
| Eisai Inc. | 14 | $242 |
| Alkermes, Inc. | 8 | $157 |
| Merck | 8 | $134 |
| Axsome Therapeutics, Inc. | 5 | $95 |
| Corium, LLC | 6 | $85 |
| Tris Pharma Inc | 5 | $83 |
| Shire North American Group Inc | 5 | $71 |
| E.r. Squibb & Sons, L.L.C. | 3 | $70 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Bausch Health US, LLC | 3 | $49 |
| Almatica Pharma LLC | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Indivior Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,010 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 37 | $297,656 |
| VraylarCariprazine Hcl | 148 | $238,115 |
| NuedextaDextromethorphan Hbr/Quinidine | 31 | $41,653 |
| Abilify MaintenaAripiprazole | 12 | $37,649 |
| RexultiBrexpiprazole | 24 | $35,428 |
| Invega SustennaPaliperidone Palmitate | 13 | $31,874 |
| TrintellixVortioxetine Hydrobromide | 30 | $16,086 |
| VyvanseLisdexamfetamine Dimesylate | 40 | $16,027 |
| Aripiprazole | 166 | $13,629 |
| Lisdexamfetamine Dimesylate | 44 | $8,646 |
| Quetiapine Fumarate | 373 | $8,008 |
| Trazodone Hcl | 372 | $7,177 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 166 | $6,725 |
| Olanzapine OdtOlanzapine | 23 | $6,640 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 197 | $5,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $644 | $297,65637 claims |
| AbbVieVraylar | $1,426 | $238,115148 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $690 | $73,07736 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $277 | $41,65331 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,059 | $32,11270 claims |
| Johnson & JohnsonInvega Sustenna | $727 | $31,87413 claims |
| MerckBelsomra | $134 | $5,71713 claims |
| Almatica Pharma LLCSertraline Hcl | $38 | $1,170160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Festus
- Eric CarbonellFestus$5.4M
- Gregory MattingleySaint Charles$8.2M
- Junaid SyedSaint Louis$8M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Franco SicuroOlivette$2.3M
- Howard IlivickySaint Charles$2.1M
- Vadim BaramSaint Louis$1.9M
- Gary LinkerFordland$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.